Forbes December 25, 2020
Sai Balasubramanian, J.D.

Verily announced late last week that it just completed a fresh investment round and has raised nearly $700 million in funding from prominent investors. The funding comes at a time when the healthcare and life-sciences industries are facing multiple stressors, especially in the context of Covid-19 and the transforming landscape of clinical medicine.

Verily is a cutting-edge organization with a broad vision. Its interests include spearheading life-sciences research, innovation in healthcare delivery, and harnessing technology and digital tools to improve health outcomes and patient care, just to name a few.

According to the press release, “The capital will be used to support rapid expansion of some of Verily’s leading commercial businesses. These include ​Baseline​, an end-to-end ecosystem designed to make...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Digital Health, Healthcare System, Investments, Pharma / Biotech, Population Health Mgmt, Technology, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article